Chrysoeriol

Chrysoeriol

SCHEMBL293757

COc1cc(-c2cc(=O)c3c(O)cc(O)cc3o2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 7/20 1.00
CYP1A1 P04798 6/20 1.00
CYP1A2 P05177 6/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
ALDH1A1 P00352 4/20 1.00
MAPT P10636 4/20 1.00
ABCC1 P33527 3/20 1.00
POLB P06746 2/20 1.00
IP6K2 Q9UHH9 5/20 0.81
XDH P47989 4/20 0.81
IPMK Q8NFU5 4/20 0.81
HDAC6 Q9UBN7 3/20 0.81
KDM1A O60341 1/20 0.81
MAOA P21397 4/20 0.77
AKR1B1 P15121 3/20 0.77
MAPK8 P45983 1/20 0.77
POLH Q9Y253 3/20 0.73
LMNA P02545 3/20 0.73
TP53 P04637 3/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chrysoeriol SCHEMBL29411724 1.00 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2MEN1KMT2A
Chrysoeriol SCHEMBL30331803 1.00 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2MEN1KMT2A
Chrysoeriol SCHEMBL17651838 0.93 CYP1B1 (0.87) CYP1B1CYP1A1CYP1A2MEN1KMT2A
Velutin SCHEMBL5804380 0.92 CYP1B1 (0.86) CYP1B1CYP1A1CYP1A2MEN1KMT2A
Velutin SCHEMBL29928535 0.92 CYP1B1 (0.86) CYP1B1CYP1A1CYP1A2MEN1KMT2A
SCHEMBL29883103 0.92 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2MEN1KMT2A
SCHEMBL30410973 0.92 CYP1B1 (0.86) CYP1B1CYP1A1CYP1A2MEN1KMT2A
SCHEMBL2483636 0.92 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2MEN1KMT2A
SCHEMBL30365934 0.92 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2MEN1KMT2A
SCHEMBL4321016 0.92 CYP1B1 (0.86) CYP1B1CYP1A1CYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120330281-B Highland barley flavonoid compound glycosyltransferase gene and application thereof INSTITUTE OF AGRICULTURE, TIBET AUTONOMOUS REGION ACADEMY OF AGRICULTURE AND ANIMAL HUSBANDRY (CN) 2026-05-26 CN claimed
US-20260077276-A1 METHODS TO CONVERT THCA INTO THC NATURAL EXTRACTION SYS LLC (US) 2026-03-19 US claimed
EP-4698662-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2026-02-25 EP claimed
US-20250381166-A1 Cannabis-Derived Flavonoids And Related Methods CANURTA INC (CA) 2025-12-18 US claimed
US-20250351836-A1 SEED EXTRACT FOR USE DURING FOOD COOKING AND STORAGE PROCESSES Khalifa University of Science and Technology (AE) 2025-11-20 US claimed
WO-2025227265-A1 METHODS FOR CONCENTRATING POLYPHENOLIC COMPOUNDS CANURTA INC. (CA) 2025-11-06 WO claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
CN-120131696-A Application of chrysoeriol alliance nofin in preparation of anti-melanoma medicine 成都大学 2025-06-13 CN claimed
CN-116381117-B Method for constructing map of snakegourd, allium macrostemon and pinellia tuber Shang Zhiwen and measuring content of index components 澳门科技大学 2025-05-30 CN claimed
CN-120060043-A Bacillus subtilis and application thereof 内蒙古农业大学 2025-05-30 CN claimed
WO-2002049575-A2 METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY THE QUIGLEY CORPORATION (US) 2002-06-27 WO claimed
WO-2001051482-A1 EXTRACTION OF FLAVONOIDS BIOREX HEALTH LIMITED (AU) 2001-07-19 WO claimed
US-6217875-B1 ETHANOL EXTRACT OF PERILLA SEEDS ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2001-04-17 US claimed
EP-1055408-A1 Sorbate preserved compositions, process for their manufacture and their use Nutrinova Nutrition Specialties & Food Ingredients GmbH (DE) 2000-11-29 EP claimed
EP-0290442-A4 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. CHEMEX PHARMACEUTICALS INC (US) 1990-07-03 EP claimed
EP-0290442-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-11-17 EP claimed
US-4774229-A ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT CHEMEX PHARMACEUTICALS, INC. (US) 1988-09-27 US claimed
WO-1988003805-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 WO claimed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 WO claimed
US-4617293-A Flavonoid phosphate salts of aminoglycoside antibiotics MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1986-10-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077276-A1 METHODS TO CONVERT THCA INTO THC CNR2, CNR1, FAAH CYP1B1 267/4885CYP1A1 124/4885CYP1A2 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.